These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
533 related items for PubMed ID: 30588564
1. Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. Patel SS, Siddiqui MS. Drugs; 2019 Jan; 79(1):75-84. PubMed ID: 30588564 [Abstract] [Full Text] [Related]
2. Future therapy for non-alcoholic fatty liver disease. Issa D, Patel V, Sanyal AJ. Liver Int; 2018 Feb; 38 Suppl 1():56-63. PubMed ID: 29427492 [Abstract] [Full Text] [Related]
4. Current and future treatment options in non-alcoholic steatohepatitis (NASH). Lazaridis N, Tsochatzis E. Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):357-369. PubMed ID: 28276821 [Abstract] [Full Text] [Related]
5. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies. Pallayova M, Taheri S. Clin Obes; 2014 Oct; 4(5):243-53. PubMed ID: 25825857 [Abstract] [Full Text] [Related]
6. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C. World J Gastroenterol; 2014 Dec 07; 20(45):16841-57. PubMed ID: 25492998 [Abstract] [Full Text] [Related]
7. [Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016]. Pár A, Pár G. Orv Hetil; 2016 Jun 19; 157(25):987-94. PubMed ID: 27287838 [Abstract] [Full Text] [Related]
8. Modern approach to the clinical management of non-alcoholic fatty liver disease. Del Ben M, Polimeni L, Baratta F, Pastori D, Loffredo L, Angelico F. World J Gastroenterol; 2014 Jul 14; 20(26):8341-50. PubMed ID: 25024593 [Abstract] [Full Text] [Related]
9. Practical approach to non-alcoholic fatty liver disease in patients with diabetes. Tai FW, Syn WK, Alazawi W. Diabet Med; 2015 Sep 14; 32(9):1121-33. PubMed ID: 25683343 [Abstract] [Full Text] [Related]
10. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C. Metabolism; 2017 Jun 14; 71():17-32. PubMed ID: 28521870 [Abstract] [Full Text] [Related]
11. Treatment of non-alcoholic fatty liver disease - Current perspectives. Elhence A, Shalimar. Indian J Gastroenterol; 2020 Feb 14; 39(1):22-31. PubMed ID: 32152902 [Abstract] [Full Text] [Related]
12. Current management of non-alcoholic fatty liver disease. Lisboa QC, Costa SM, Couto CA. Rev Assoc Med Bras (1992); 2016 Dec 14; 62(9):872-878. PubMed ID: 28001263 [Abstract] [Full Text] [Related]